| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/16/2005 | US20050131002 Anticholesterol agents; antilipemic agents; cardiovascular disorders; antiischemic agents; anticancer agents |
| 06/16/2005 | US20050131001 Anticholesterol agents; antilipemic agents; antiischemic agents; cardiovascular disorders |
| 06/16/2005 | US20050131000 Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino)pyrimidine with cdk inhibitory activity |
| 06/16/2005 | US20050130999 Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins |
| 06/16/2005 | US20050130998 Central nervous ystem diorders; Alzheimer's disease ; anticancer agents |
| 06/16/2005 | US20050130997 Pyrimidinone viral polymerase inhibitors |
| 06/16/2005 | US20050130996 5-(4-{3-chloro-4-(3-fluorobenzyloxy)-anilino}-6-quinazolinyl)-furan-2-carbaldehyde; selective inhibition of the protein tyrosine kinase activity, minimising side effects |
| 06/16/2005 | US20050130994 Antiproliferative agents; skin, prostate glands, kidneys, central nervous system |
| 06/16/2005 | US20050130993 Synthesis and purification of valacyclovir |
| 06/16/2005 | US20050130990 especially dimethylphenylpiperazinium; treating a variety of pulmonary diseases with fewer side effects than other anti-inflammatory drugs, such as steroids |
| 06/16/2005 | US20050130988 Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders; modulating energy homeostasis in a mammal without eliciting a sexual response |
| 06/16/2005 | US20050130987 Methods of treating vasomotor symptoms |
| 06/16/2005 | US20050130986 Treatment of spondylarthropathies |
| 06/16/2005 | US20050130985 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition |
| 06/16/2005 | US20050130982 4-isopropyl-2-methoxy-7-[4-(2-pyrimidyl)piperazinomethyl]-2,4,6-cycloheptatrien-1-one |
| 06/16/2005 | US20050130981 Compounds |
| 06/16/2005 | US20050130979 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) or the quinoxalinedione is 9-methyl-amino-6-nitro-hexahydro-benzo(F) quinoxalinedione (PNQX) for treating demyelinating disorders |
| 06/16/2005 | US20050130977 Inhibitors of akt activity |
| 06/16/2005 | US20050130976 Bicyclic inhibitors of MEK and methods of use thereof |
| 06/16/2005 | US20050130975 Phthalazine, hydralazine derivative; antihypertensive; extended shell life |
| 06/16/2005 | US20050130974 Benzothiazole compositions and their use as ubiquitin ligase inhibitors |
| 06/16/2005 | US20050130972 Derivatives have a positive charge at the position corresponding to the anomeric position of a pyranose ring; active-site specific chaperones for mutant glucocerebrosidase |
| 06/16/2005 | US20050130971 Cyclooxygenase inhibitors are chromene derivative compounds, benzothiopyrans, dihydroquinolines, dihydronaphthalenes; phosphodiesterase inhibitors are tricyclic sulfonamide derivatives |
| 06/16/2005 | US20050130970 Thiazoles and oxazoles useful as modulators of ATP-Binding Cassette transporters |
| 06/16/2005 | US20050130967 3-Substituted-4-pyrimidone derivatives |
| 06/16/2005 | US20050130966 Sodium channel modulators |
| 06/16/2005 | US20050130965 Inhibitors of p38 kinase |
| 06/16/2005 | US20050130964 e.g 8-oxa-1-thia-benzo[e]naphtho[3,2-h]azulene-2-carboxylic acid ethyl ester; rheumatoid arthritis |
| 06/16/2005 | US20050130963 Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity |
| 06/16/2005 | US20050130962 Seratonin receptor antagonist; central nervous system disorders; halo phenyl substituents |
| 06/16/2005 | US20050130961 Muscarinic M1 receptor agonists for pain management |
| 06/16/2005 | US20050130960 (S)-2-(8,9-dihydro-9-methyl-7H-[1,4]oxazino[2,3-g]indazol-1-yl)-1-methylethylamine fumarate for example; 5-HT2 agonists |
| 06/16/2005 | US20050130959 Selective in presence of at least one other cathepsin isozyme; such as (3-cyclopentyl-{[5-(3-fluoro-phenyl)-furan-2-carbonyl]-amino}-propionylamino)-4-oxo-butyric acid |
| 06/16/2005 | US20050130957 Novel substituted pyrazolo[4,3-e]diazepines, pharmaceutical compositions containing them, use as medical products and processes for preparing them |
| 06/16/2005 | US20050130956 1-oxa 3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof |
| 06/16/2005 | US20050130954 Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline |
| 06/16/2005 | US20050130952 Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases |
| 06/16/2005 | US20050130951 Use of Manganese(II) complexes of substituted, unsaturated heterocyclic pentaazacyclopentadecane ligands |
| 06/16/2005 | US20050130948 Therapeutic methods and uses of sapogenins and their derivatives |
| 06/16/2005 | US20050130947 6alpha, 9alpha-Difluoro-17alpha-((2-furanylcarbonyl)oxy)-11beta-hydroxy-16alpha-methyl-3-oxo-androsta-1,4-diene-17beta-carbothioic acid S-fluoromethyl ester completely dissolved in a liquified hydrofluoroalkane (HFA) gas as propellant; for asthma or chronic obstructive pulmonary disease (COPD) |
| 06/16/2005 | US20050130946 Metabolite |
| 06/16/2005 | US20050130945 Preventing recurrence of breast cancer with atamestane and toremifene |
| 06/16/2005 | US20050130944 Method of making and using 7alpha,11beta-dimethyl-17beta-hydroxyestr-4-en-3-one 17-undecanoate |
| 06/16/2005 | US20050130943 Bicyclic inhibitors of MEK and methods of use thereof |
| 06/16/2005 | US20050130942 (E)-2,4,6-trimethoxystyryl-4-methoxy-3-aminobenzylsulfone for example; cancer, tumors, multiple sclerosis, Pagets disease; antibody conjugates; target receptor tyrosine kinases and which arrest the Ras/Raf/MEK/ERK kinase cascade |
| 06/16/2005 | US20050130941 Methods of treating alzheimer's disease |
| 06/16/2005 | US20050130940 Fungal infections; water soluble phosphate derivatives of triazole drugs such as fluconazole |
| 06/16/2005 | US20050130939 Substituted fullerene compositions and their use as antioxidants |
| 06/16/2005 | US20050130938 Method for alleviating syndromes and conditions of discomfort of the mammalian intestinal and genito-urinary tracts |
| 06/16/2005 | US20050130937 Glycerophospholid esters of polyunsaturated fatty acid (PUFA); increased bioavailability of PUFA; use as pharmaceutical, nutraceutical e.g. neurodegenerative disorders; less fish-related organoleptic effects |
| 06/16/2005 | US20050130935 Combination of a beta-2-adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders |
| 06/16/2005 | US20050130934 Antibacterial agents and process for producing the same |
| 06/16/2005 | US20050130933 As satiety-promoting ingredient dietary fiber as glucomannan and a gum, and a thermogenic ingredient of caffeine and/or a catechin-polyphenol such as epigallocatechin gallate (EGCG) |
| 06/16/2005 | US20050130932 Viscoelastic preparations comprise 1.0-12.0 percent by weight of glycated chitosan in an aqueous solution; eye drops; bioresorbable; antibacterial properties |
| 06/16/2005 | US20050130931 Compositions for the treatment of glaucoma or ocular hypertension |
| 06/16/2005 | US20050130930 Adenosine derivatives and use thereof |
| 06/16/2005 | US20050130929 For introduction of a disc prosthesis or implant; involves providing substance(s) beneficial to the intervertebral disc through a cannulated element |
| 06/16/2005 | US20050130927 For treating neoplasm, hypoproliferation, hyperproliferation, degenerative and neurodegenerative diseases, ischaemia, immune system disorder, infectious disease, or metabolic dysfunction |
| 06/16/2005 | US20050130925 Transduction; prostaglandins E1 (PGE1); introducing a recombinant cDNA encoding at least one cyclooxygenase isoform into the cells such that cells overexpress cyclooxygenase isoform then treating cells with fatty acid substrate |
| 06/16/2005 | US20050130923 4'-thionucleosides and oligomeric compounds |
| 06/16/2005 | US20050130915 Polymorphic antiviral nucleoside compounds |
| 06/16/2005 | US20050130914 Methods of administering dalbavancin for treatment of skin and soft tissue infections |
| 06/16/2005 | US20050130912 Compositions for the improvement of obesity |
| 06/16/2005 | US20050130910 Antitumor agents; restenosis; antiarthritic agents; antidiabetic agents; drug screening |
| 06/16/2005 | US20050130909 Gram-positive bacterial infection of skin and soft tissue; soluble |
| 06/16/2005 | US20050130908 Treatment or amelioration of depression; provides better bioavailability |
| 06/16/2005 | US20050130906 Amelioration of macular degeneration and other ophthalmic diseases |
| 06/16/2005 | US20050130903 Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| 06/16/2005 | US20050130900 Sustained release drug formulations containing a carrier peptide |
| 06/16/2005 | US20050130891 Containing at least two of the following active substances A, B, C, wherein: A=at least one hormone stimulating the production of cAMP; B=at least one substance inhibiting the degradation of a cyclic nucleotide; C=at least one hormone stimulating the production of cGMP |
| 06/16/2005 | US20050130882 Combination therapy including 9-nitro-20(S)-camptothecin |
| 06/16/2005 | US20050130881 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 06/16/2005 | US20050130880 zinc(II) organic complex with ligands selected from aminoalkylpyridines, bis-optically active amino acids, bisaminoalkylcarboxylic acids, oligopeptides, oligopseudopeptides, di-substituted aminocarboxylic acids, alpha - and beta -hydroxycarboxylic acids, vitamins, glutamine; insulin mimetics; less toxic; |
| 06/16/2005 | US20050130879 Modifying tissue surfaces by liquid crystal formation |
| 06/16/2005 | US20050130878 Prevention of photic injury by administering a TACE inhibitor |
| 06/16/2005 | US20050130877 Axon regeneration with PKC inhibitors |
| 06/16/2005 | US20050130304 Regulation of endogenous gene expression in cells using zinc finger proteins |
| 06/16/2005 | US20050130238 ErbB surface receptor complexes as biomarkers |
| 06/16/2005 | US20050130221 Synthesis for the preparation of compounds for screening as potential tubulin binding agents |
| 06/16/2005 | US20050130209 Expression vector comprising nucleotide sequences coding deoxyribonuclease for use as tool in treatment and prevention of cystic fibrosis |
| 06/16/2005 | US20050130195 Functional molecule and process for producing the same |
| 06/16/2005 | US20050130193 Methods for detecting, diagnosing and treating human renal cell carcinoma |
| 06/16/2005 | US20050130130 Killer cell activatory receptor ligand for use in diagnosis, prevention and treatment of infection, cell proliferative, autoimmune and arthritic disorders |
| 06/16/2005 | US20050129830 Fatty acid glycerides; dietetics |
| 06/16/2005 | US20050129791 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
| 06/16/2005 | US20050129790 Cardiovascular disorders |
| 06/16/2005 | US20050129785 Side effect reduction; synergistic mixtures |
| 06/16/2005 | US20050129783 Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health |
| 06/16/2005 | US20050129781 Colonic purgative composition with soluble binding agent |
| 06/16/2005 | US20050129780 Relief of aids symptoms |
| 06/16/2005 | US20050129777 Liquid phase emulsion upon dilution; controlling particle size; drug delivery; anticancer agents; pain maintenance ; immunosuppressant; antidiabetic agents |
| 06/16/2005 | US20050129774 Mixture with surfactant and another drug; analgesics; antiinflammatory agents |
| 06/16/2005 | US20050129773 Acne; skin disorders; controlling particle sizes |
| 06/16/2005 | US20050129772 Using n-allyl-3-(2-hydroxy-3-(3-hydroxy-2-methylbenzoylamino)-4-phenylbutanoyl)-5,5-dimethyl-1,3-thiazolidine-4-carboxamide |
| 06/16/2005 | US20050129771 Ophthalmic compositions containing a polysaccharide/borate gelling system |
| 06/16/2005 | US20050129768 Using a oxyamidine phenyl compound as leukotriene antagonist |
| 06/16/2005 | US20050129767 Antifungal formulation and manufacturing method thereof |
| 06/16/2005 | US20050129765 Exterior semipermeable membrane with aperture; antidiabetic agents; eating disorders; antidiabetic agents; headaches |
| 06/16/2005 | US20050129764 Antiarthritic agents; antiinflammatory agents; bronchitis; skin disorders; inflamamtory bowel disorders; cyclooxygenase inhibitors |
| 06/16/2005 | US20050129762 Oral delivery to mammals; venlafaxine ; antidepressants; anxiolytic agents |